Clinical trial
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
NCT00431912 · Valerio Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00431912 |
|---|---|
| Title | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma |
| Official title | A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma |
| Lead sponsor | Valerio Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | APO866 |
| Enrollment | 25 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Feb 6, 2007 |
| Last update posted | Jul 8, 2015 |
| Countries | Austria, France, Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: